Article Text

other Versions

PDF
Predicted Biological Activity of Intravitreal VEGF TRAP
  1. Michael W Stewart (stewart.michael{at}mayo.edu),
  2. Philip J Rosenfeld
  1. Mayo Clinic Jacksonville, United States
  2. Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, United States

    Abstract

    Aims: To compare the intravitreal binding activity of the VEGF TRAP with that of ranibizumab against VEGF (vascular endothelial growth factor) using a time and dose-dependant mathematical model

    Methods: Intravitreal half-lives and relative equimolar VEGF binding activities of the VEGF TRAP and ranibizumab were incorporated into a first-order decay model. Time-dependant VEGF TRAP activities (relative to ranibizumab) for different initial doses (0.5 mg, 1.15 mg, 2 mg, 4 mg) were calculated and graphed

    Results: Seventy-nine days following a single VEGF TRAP (1.15 mg) injection, the intravitreal VEGF binding activity would be comparable to ranibizumab at 30 days. Following VEGF TRAP injections of 0.5 mg, 2 mg and 4 mg, the intravitreal VEGF binding activities (comparable to ranibizumab at 30 days) would occur at 73 days, 83 days and 87 days respectively

    Conclusion: Based upon this mathematical model, the VEGF TRAP maintains a significant intravitreal VEGF binding activity for 10 to 12 weeks following a single injection.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.